The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: Is tyramine a challenge?

Journal of Clinical Pharmacology

Volumn 52, Issue 5, 2012, Pages 620-628

  Chen, Jack J ^a   Wilkinson, Jayne R ^b,c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

monoamine oxidase; Parkinson disease; Rasagiline; tyramine

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ALCOHOL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBIDOPA; EPHEDRINE; LEVODOPA; PHENELZINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PLACEBO; RASAGILINE; SELEGILINE; TRANYLCYPROMINE; TRANYLCYPROMINE PLUS TRIFLUOPERAZINE; TYRAMINE;

ADD ON THERAPY; ADJUVANT THERAPY; BEER; BLOOD PRESSURE MEASUREMENT; CHEESE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVITY; FLUSHING; GENERAL ANESTHESIA; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; LOCAL ANESTHESIA; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA; RED WINE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; VICIA FABA; VOMITING; YEAST;

ANTIPARKINSON AGENTS; BRAIN; DIETARY PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD-DRUG INTERACTIONS; HUMANS; HYPERTENSION; INDANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TYRAMINE;

EID: 84860303672     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011406279     Document Type: Review

References (64)

1. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 ; 29: 1825-1849 (Pubitemid 350212811)
2. Elmer LW, Bertoni JM. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. Expert Opin Pharmacother. 2008 ; 9: 2759-2772
3. Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988 ; 26: 31-56
4. Baxter K Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management. 8 th ed.London, England: Pharmaceutical Press; 2008. London, England: Pharmaceutical Press ; 2008:
5. Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007 ; 3: 527-537 (Pubitemid 350090283)
6. Feldstein C. Management of hypertensive crises. Am J Ther. 2007 ; 14: 135-139 (Pubitemid 46597650)
7. Fort Lee, NJ: DAVA Pharmaceuticals, Inc ; 2007:
8. Kansas City, MO: Teva Neuroscience, Inc ; 2009:
9. McGrath PJ, Stewart JW, Quitkin FM. A possible L-deprenyl induced hypertensive reaction [letter]. J Clin Psychopharmacol. 1989 ; 9: 310-311
10. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997 ; 48: 1070-1077
11. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997 ; 9: 7-13 (Pubitemid 27425014)
12. Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann Pharmacother. 2000 ; 34: 1020-1024 (Pubitemid 30660779)
13. Ito D, Amano T, Sato H, Fukuuchi Y. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease [letter]. J Neurol. 2001 ; 248: 533-534 (Pubitemid 32661513)
14. Weintraub D, Comella CL, Horn S. Parkinson's disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008 ; 14: S40 - S48
15. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005 ; 28: 57-87 (Pubitemid 41098899)
16. Oreland L, Arai Y, Stenström A. The effect of deprenyl (selegiline) on intra- and extraneuronal dopamine oxidation. Acta Neurol Scand Suppl. 1983 ; 95: 81-85 (Pubitemid 14162446)
17. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 ; 58: 11-17 (Pubitemid 34041931)
18. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 ; 66: 983-995 (Pubitemid 44044780)
19. deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006 ; 21: 1716-1721 (Pubitemid 44742203)
20. Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase inhibitor type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010 ; 50: 1420-1428
21. White WB, Salzman P, Schwid SR. Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off" Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension. 2008 ; 52: 587-593
22. Wilkinson J, Reichwein S, Stern M. Safety and tolerability of tyramine challenge in levodopa-treated Parkinson's disease (PD) patients receiving rasagiline. Presented at: American Academy of Neurology Annual Meeting ; Chicago, IL ;..
23. Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm. 2003 ; 110: 1257-1271 (Pubitemid 37500747)
24. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl). 1978 ; 57: 33-38 (Pubitemid 8338582)
25. Pickar D, Cohen RM, Jimerson DC, Murphy DL. Tyramine infusions and selective monoamine oxidase inhibitor treatment: I. Changes in pressor sensitivity. Psychopharmacology (Berl). 1981 ; 74: 4-7 (Pubitemid 11126451)
26. Stern GM, Lees AJ, Sandler M. Recent observations on the clinical pharmacology of (-)deprenyl. J Neural Transm. 1978 ; 43: 245-251 (Pubitemid 9050085)
27. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl). 1985 ; 86: 432-437 (Pubitemid 15042307)
28. LeWitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology. 2009 ; 72: 1352-1357
29. Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 ; 113: 349-365
30. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963 ; 2: 849-851
31. Blackwell B, Marley E, Ryle A. Hypertensive crisis associated with monoamine-oxidase inhibitors [letter]. Lancet. 1964 ; 283: 722-723
32. Hodge JV, Nye ER, Emerson GW. Monoamine-oxidase inhibitors, broad beans, and hypertension [letter]. Lancet. 1964 ; 283: 1108
33. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989 ; 9: 397-402 (Pubitemid 20023019)
34. Suzzi G, Gardini F. Biogenic amines in dry fermented sausages: a review. Int J Food Microbiol. 2003 ; 88: 41-54 (Pubitemid 37188430)
35. Walker SE, Shulman KI, Tailor SA, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol. 1996 ; 16: 383-388 (Pubitemid 26352668)
36. Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D. Hypertensive episode associated with phenelzine and tap beer-a reanalysis of the role of pressor amines in beer. J Clin Psychopharmacol. 1994 ; 14: 5-14 (Pubitemid 24076176)
37. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999 ; 60: 191-193 (Pubitemid 29168693)
38. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964 ; 188: 1108-1110
39. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl. 1989 ; 28: 21-31
40. Westfall TC, Westfall DP Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11 th ed.New York, NY: McGraw-Hill; 2006:240. Brunton LL Lazo JS Parker KL, ed. New York, NY: McGraw-Hill ; 2006: 240.
41. Cuthbert MF, Greenberg MP, Morley SW. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J. 1969 ; 1: 404-406
42. Schulz R, Antonin K-H, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989 ; 46: 528-536 (Pubitemid 20009869)
43. Bieck PR, Antonin K-H. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol. 1988 ; 8: 237-245
44. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989 ; 46: 344-351 (Pubitemid 19254768)
45. Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol. 1988 ; 11: 17-23 (Pubitemid 18020871)
46. Zimmer R. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Acta Psychiatr Scand Suppl. 1990 ; 360: 81-83 (Pubitemid 20320306)
47. VanDenBerg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003 ; 43: 604-609 (Pubitemid 36613119)
48. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm Suppl. 1988 ; 26: 57-71
49. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001 ; 132: 500-506 (Pubitemid 32142364)
50. Hubálek F, Binda C, Li M, et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem. 2004 ; 47: 1760-1766 (Pubitemid 38380919)
51. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996 ; 48: 95-101 (Pubitemid 26423350)
52. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998 ; 52: 301-305
53. Westfall TC, Westfall DP Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11 th ed.New York, NY: McGraw-Hill; 2006:165. Brunton LL Lazo JS Parker KL, ed. New York, NY: McGraw-Hill ; 2006: 165.
54. Berlin I, Zimmer R, Thiede H-M, et al. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 ; 30: 805-816
55. Holford NH, Guentert TW, Dingemanse J, Banken L. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol. 1994 ; 37: 433-439 (Pubitemid 24197136)
56. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol. 1989 ; 27: 243-255 (Pubitemid 19059488)
57. Radat F, Berlin I, Spreux-Varoquaux O, Elatki S, Ferreri M, Puech AJ. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression: a double blind, randomized study. Psychopharmacology (Berl). 1996 ; 127: 370-376 (Pubitemid 26356764)
58. Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS. Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Mov Disord. 2008 ; 23: 1725-1732
59. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002 ; 59: 1937-1943
60. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 ; 62: 241-248
61. Olanow CW, Rascol O, Hauser R. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 ; 361: 1268-1278
62. Rascol O, Brooks DJ, Melamed E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005 ; 365: 947-954 (Pubitemid 41071428)
63. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 ; 61: 561-566
64. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 ; 24: 564-573